Latigo Biotherapeutics priced its upsized $345.6 million IPO on August 6, 2026, at $18 per share after initially targeting a $1.08 billion valuation with shares at $16–18, producing an estimated closing market capitalization near $1.14 billion. Strong institutional demand, supported by positive Phase 2 data for its Nav1.8 inhibitor LTG-001 and a favorable biotech IPO window, drove the upsizing and alignment with the $1.15–1.3 billion range. Trader consensus reflects the skin-in-the-game pricing outcome and recent share gains above $21 on debut. Potential challenges include sharp post-IPO volatility from broader market sentiment shifts, clinical setbacks in planned Phase 3 trials, or dilution from future capital raises that could pressure the realized capitalization below this band.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว$1.15B-$1.3B 100.0%
$1.3B-$1.45B 1.9%
$1.45B+ 1.9%
$1B-$1.15B <1%
$1,974 ปริมาณ
$1,974 ปริมาณ
Aug 7, 2026
<$850M
No
$850M-$1B
No
$1B-$1.15B
No
$1.15B-$1.3B
Yes
$1.3B-$1.45B
No
$1.45B+
No
No IPO before October 2026
No
$1.15B-$1.3B 100.0%
$1.3B-$1.45B 1.9%
$1.45B+ 1.9%
$1B-$1.15B <1%
$1,974 ปริมาณ
$1,974 ปริมาณ
Aug 7, 2026
<$850M
$351 ปริมาณ
No
$850M-$1B
$436 ปริมาณ
No
$1B-$1.15B
$193 ปริมาณ
No
$1.15B-$1.3B
$250 ปริมาณ
Yes
$1.3B-$1.45B
$150 ปริมาณ
No
$1.45B+
$180 ปริมาณ
No
No IPO before October 2026
$414 ปริมาณ
No
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics priced its upsized $345.6 million IPO on August 6, 2026, at $18 per share after initially targeting a $1.08 billion valuation with shares at $16–18, producing an estimated closing market capitalization near $1.14 billion. Strong institutional demand, supported by positive Phase 2 data for its Nav1.8 inhibitor LTG-001 and a favorable biotech IPO window, drove the upsizing and alignment with the $1.15–1.3 billion range. Trader consensus reflects the skin-in-the-game pricing outcome and recent share gains above $21 on debut. Potential challenges include sharp post-IPO volatility from broader market sentiment shifts, clinical setbacks in planned Phase 3 trials, or dilution from future capital raises that could pressure the realized capitalization below this band.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ตลาดเปิดเมื่อ: Aug 5, 2026, 5:52 AM ET
ปริมาณการซื้อขาย
$1,974วันสิ้นสุด
Aug 7, 2026ตลาดเปิดเมื่อ
Aug 5, 2026, 5:52 AM ETResolver
0x69c47De9D...เสนอผลลัพธ์แล้ว: No
ไม่มีการคัดค้าน
ผลลัพธ์สุดท้าย: No
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics priced its upsized $345.6 million IPO on August 6, 2026, at $18 per share after initially targeting a $1.08 billion valuation with shares at $16–18, producing an estimated closing market capitalization near $1.14 billion. Strong institutional demand, supported by positive Phase 2 data for its Nav1.8 inhibitor LTG-001 and a favorable biotech IPO window, drove the upsizing and alignment with the $1.15–1.3 billion range. Trader consensus reflects the skin-in-the-game pricing outcome and recent share gains above $21 on debut. Potential challenges include sharp post-IPO volatility from broader market sentiment shifts, clinical setbacks in planned Phase 3 trials, or dilution from future capital raises that could pressure the realized capitalization below this band.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ปริมาณการซื้อขาย
$1,974วันสิ้นสุด
Aug 7, 2026ตลาดเปิดเมื่อ
Aug 5, 2026, 5:52 AM ETResolver
0x69c47De9D...เสนอผลลัพธ์แล้ว: No
ไม่มีการคัดค้าน
ผลลัพธ์สุดท้าย: No
Latigo Biotherapeutics priced its upsized $345.6 million IPO on August 6, 2026, at $18 per share after initially targeting a $1.08 billion valuation with shares at $16–18, producing an estimated closing market capitalization near $1.14 billion. Strong institutional demand, supported by positive Phase 2 data for its Nav1.8 inhibitor LTG-001 and a favorable biotech IPO window, drove the upsizing and alignment with the $1.15–1.3 billion range. Trader consensus reflects the skin-in-the-game pricing outcome and recent share gains above $21 on debut. Potential challenges include sharp post-IPO volatility from broader market sentiment shifts, clinical setbacks in planned Phase 3 trials, or dilution from future capital raises that could pressure the realized capitalization below this band.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย